Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: A possible link suggested by cross-sectional analysis

Endocrine Journal

Volumn 59, Issue 3, 2012, Pages 187-195

  Saisho, Yoshifumi ^a   Tanaka, Kumiko ^a   Abe, Takayuki ^a   Shimada, Akira ^b   Kawai, Toshihide ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

Beta cell function; C peptide; Obesity; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C PEPTIDE; INSULIN; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; SULFONYLUREA;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; IMMUNOREACTIVITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT CODING; POSTPRANDIAL STATE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; C-PEPTIDE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; RETROSPECTIVE STUDIES;

EID: 84859045371     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0206     Document Type: Article

References (24)

1. Rhodes CJ (2005) Type 2 diabetes-a matter of beta-cell life and death? Science 307: 380-384.
2. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
4. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45: 85-96.
5. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, Yoo SJ, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim HS, Lee IK, Bonner-Weir S (2003) Selective betacell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88: 2300-2308.
6. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10 Suppl 4: 32-42.
7. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258.
8. Koga M, Murai J, Saito H, Kasayama S (2010) Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care 33: 270-272.
9. Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, Itoh H (2011) Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int 2:146-153.
10. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Hamamoto Y, Hosokawa M, Seino Y, Inagaki N (2008) Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82: 353-358.
11. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495.
12. Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, Shimada A, Meguro S, Kawai T, Itoh H (2011) Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 58: 315-322.
13. The Commitee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 1: 212-228.
14. Japan Diabetes Society (2010) The guideline for the treatment of diabetes. Japan Diabetes Society, Tokyo (In Japanese).
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
16. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32-38.
17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
19. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292: 1724-1737.
20. Tsai EB, Sherry NA, Palmer JP, Herold KC (2006) The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49: 261-270.
21. Torn C (2003) C-peptide and autoimmune markers in diabetes. Clin Lab 49: 1-10.
22. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
23. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M (2005) Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54 Suppl 2: S108-113.
24. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W, Schmidt WE, Schrader H (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-1603.